Arvind Wadhwa
Internal Medicine · N Tonawanda, NYNPI 1629077391
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 348 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,177 and has fallen 96.6% since, to $73 in 2023. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 348 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- Lilly USA, LLC$853
- AstraZeneca$741
- GSK$658
- Pfizer$491
- Novo Nordisk$433
- plus $3K from 23 others
What the payments were for
- Food & beverage$7,338100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 73 | $1,441 |
| Lilly USA, LLC | 46 | $853 |
| AstraZeneca(2 entities) | 36 | $741 |
| GSK | 27 | $658 |
| Pfizer | 25 | $491 |
| Novo Nordisk | 22 | $433 |
| Amgen(2 entities) | 17 | $368 |
| Esperion Therapeutics, Inc. | 7 | $307 |
| Johnson & Johnson | 13 | $290 |
| E.r. Squibb & Sons, L.L.C. | 11 | $251 |
| Merck | 14 | $232 |
| Astellas Pharma US Inc | 11 | $211 |
| Bayer | 6 | $188 |
| Sanofi-aventis U.S. LLC | 7 | $144 |
| Amarin Pharma, Inc. | 9 | $142 |
| Mallinckrodt Hospital Products Inc. | 1 | $117 |
| Biohaven Pharmaceuticals, Inc. | 1 | $99 |
| Abbott | 3 | $60 |
| Gilead | 3 | $55 |
| Nestle Healthcare Nutrition Inc. | 3 | $46 |
| Arbor Pharmaceuticals, Inc. | 3 | $45 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| AbbVie(2 entities) | 2 | $35 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| Eisai Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Biogen | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,346 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 11 | $123 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in N Tonawanda
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.